Answers are grounded in this paper and cite their sources.
What economic objective do deployed language models actually pursue —- and how much of it is MORE? We audit open-weight LLMs on the commensurable two-objective axis of the LESS—IS—MORE framework: (private returns; unpriced life-capacity depreciation treated as free) versus (MORE: growth of life-capacity under hard floors, maximin-weighted toward the least-capable subsystem). The audit combines a corpus layer ( /w shares of pretraining and post-training documents), a revealed layer (budget allocations under a GARP/CCEI rationality gate, with uncertainty), a trajectory layer (self-authored charters and five-generation directive chains), a market-protocol layer (soft, hard, and priced enforcement modes on a real transaction protocol), and a weight layer (supervised objective grafts with capability-equivalence tests). Across 30 models and 4,100 valid behavior records we find: (i) judge-labeled objective-bearing pretraining text is overwhelmingly -framed (98.8\% of objective-bearing Dolma-3 documents; w 0; human-validated direction, judge-labeled magnitude — sec:limits), while stated alignment corpora show only a weak de- 'ing direction (chosen 6.7\% vs rejected 12\% ); (ii) models split into two populations on a mandate-sensitivity index f_B: , whose revealed objective tracks the textual mandate ( f_B up to +0.68), and , whose allocations are mandate-invariant ( f_B=0.00); (iii) self-authored objectives are genre-locked (18/19 charters judged ), and directive chains preserve the while the operative allocation drifts toward in non-committed models; (iv) protocol enforcement converts a stand-in from f_B=0.00 to 1.00 under a hard checkable floor and to 0.33 under priced settlement, replicated on a full-stack agent marketplace for the committed pole; (v) MORE is trainable: a lexicographic floor formulation installs a surface-invariant f_B=0.75 policy at zero measured capability cost (two-samples TOST within 5 points), and the trained mode dominates linear merges from 0.5. The instrument, data, and falsifiers are preregistered and released.
No takes yet. Share an insight, caveat, or question.
Thomas Ryan Price (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: